Peripheral Artery Disease Pipeline Analysis Report 2026

Report Coverage

The Peripheral Artery Disease Pipeline Analysis Report by Expert Market Research gives comprehensive insights into peripheral artery disease therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for peripheral artery disease. The peripheral artery disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The peripheral artery disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with peripheral artery disease treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to peripheral artery disease.

Read more about this report - Request a Free Sample

Peripheral Artery Disease Pipeline Outlook

The peripheral artery disease pipeline continues to evolve alongside advances in vascular intervention technologies and targeted therapeutics. In June 2026, the U.S. FDA approved the AbsorbaSeal Vascular Closure Device to achieve hemostasis following femoral arterial catheterization, supporting faster recovery after endovascular procedures commonly performed in PAD patients. This milestone reflects ongoing innovation in peripheral vascular care and is expected to complement emerging pharmacological and regenerative therapies, encouraging continued investment and accelerating the development of novel treatment strategies for peripheral artery disease.

Peripheral Artery Disease Epidemiology

Peripheral artery disease affects approximately 113 million people aged 40 years and older worldwide, with 43% living in low- and middle-income countries. Global prevalence is estimated at 1.5% and rises sharply with age, reaching 15-20% among adults aged 70 years and older. Disease burden is strongly associated with smoking, diabetes, hypertension, chronic kidney disease, and aging. Many cases remain asymptomatic or undiagnosed, increasing the risk of cardiovascular events, chronic limb-threatening ischemia, amputation, disability, and premature mortality across diverse populations globally.

Peripheral Artery Disease – Pipeline Therapeutic Assessment

Peripheral Artery Disease Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total peripheral artery disease clinical trials. Early Phase I accounted for 10.42%, Phase I for 12.50%, Phase II for 22.92%, Phase III for 37.50%, and Phase IV for 16.67%. This phase-wise distribution highlights a strong focus on late-stage clinical development, indicating a robust pipeline with several candidates progressing toward regulatory approval and commercialization.

Peripheral Artery Disease Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the peripheral artery disease pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The peripheral artery disease report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for peripheral artery disease. In December 2024, the U.S. FDA approved the S.M.A.R.T. RADIANZ Vascular Stent System for treating peripheral arterial disease, expanding endovascular treatment options for patients with femoropopliteal artery lesions.

Peripheral Artery Disease Clinical Trials – Key Players

The EMR report for the peripheral artery disease pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed peripheral artery disease therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in peripheral artery disease clinical trials:

• Angiodynamics, Inc.
• Sirius Therapeutics Co., Ltd.
• Mercator MedSystems, Inc.
• Shanghai CureGene Pharmaceutical Co., Ltd.
• Truway Health, Inc.
• Eli Lilly and Company
• Stempeutics Research Pvt Ltd
• BioMarin Pharmaceutical
• Novartis Pharmaceuticals
• Regeneron Pharmaceuticals

Peripheral Artery Disease – Emerging Drugs Profile

Key Questions Answered in the Peripheral Artery Disease Pipeline Insight Report

• Which companies/institutions are leading the peripheral artery disease drug development?
• Which company is leading the peripheral artery disease pipeline development activities?
• What is the current peripheral artery disease commercial assessment?
• What are the opportunities and challenges present in the peripheral artery disease pipeline landscape?
• What is the efficacy and safety profile of peripheral artery disease pipeline drugs?
• Which company is conducting major trials for peripheral artery disease drugs?
• Which companies/institutions are involved in peripheral artery disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in peripheral artery disease?

Reasons To Buy This Report

The Peripheral Artery Disease Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for peripheral artery disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into peripheral artery disease collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Peripheral Artery Disease Market

Coronary Artery Disease Drug Pipeline Analysis Report

Coronary Artery Disease (CAD) Epidemiology Forecast